Vor Biopharma Inc. Logo

Vor Biopharma Inc.

Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.

VOR | US

Overview

Corporate Details

ISIN(s):
US9290331084
LEI:
Country:
United States of America
Address:
500 BOYLSTON STREET, 2116 BOSTON

Description

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing a new generation of medicines for autoimmune diseases. The company is advancing breakthrough science to create treatments that go beyond symptom control by targeting the fundamental drivers of autoimmunity. Its lead program features telitacicept, a therapy designed to silence the signals that allow harmful immune cells to survive, with the goal of delivering safer, longer-lasting treatments. Vor Bio aims to restore balance to the immune system and meaningfully improve the lives of patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vor Biopharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vor Biopharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vor Biopharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain
IKM
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation platform for designing and optimizing biologic therapeutics.
United States of America
ABSI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland
ACHI
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.